Alvotech - (ALVO) closed at $5.13 on October 21, 2026, up 0.2% from the previous close, on volume of 450,778 shares (30-day average 1,164,825).
Data as of October 21, 2026.
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and Alvotech (ALVO)
TipRanks (Tue, 20-Oct 10:01 AM ET)
Alvotech Wins FDA Nod for High-Yield SIMLANDI Manufacturing Upgrade
TipRanks (Tue, 20-Oct 8:32 AM ET)
Alvotech wins FDA nod for new manufacturing process for Humira biosimilar
Seeking Alpha News (Tue, 20-Oct 8:02 AM ET)
Globe Newswire (Tue, 20-Oct 4:30 AM ET)
Globe Newswire (Wed, 14-Oct 4:30 AM ET)
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Globe Newswire (Tue, 6-Oct 4:36 PM ET)
ALVO Rallies After FDA Clears a Second Reykjavik Suite for SIMLANDI U.S. Supply
Market Chameleon (Mon, 5-Oct 6:30 AM ET)
FDA approves additional U.S. manufacturing capacity for SIMLANDI, Alvotech's biosimilar to Humira
Globe Newswire (Mon, 5-Oct 4:00 AM ET)
Globe Newswire (Mon, 31-Aug 4:30 AM ET)
Alvotech to present at upcoming investor conferences in September
Globe Newswire (Thu, 27-Aug 8:00 AM ET)
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Alvotech - trades on the NASDAQ stock market under the symbol ALVO.
As of October 21, 2026, ALVO stock price climbed to $5.13 with 450,778 million shares trading.
ALVO has a beta of 1.23, meaning it tends to be more sensitive to market movements. ALVO has a correlation of 0.05 to the broad based SPY ETF.
ALVO has a market cap of $1.74 billion. This is considered a Small Cap stock.
Last quarter Alvotech - reported $106 million in Revenue and -$.17 earnings per share. This beat revenue expectation by $545,824 and missed earnings estimates by -$.09.
In the last 3 years, ALVO traded as high as $18.00 and as low as $2.94.
The top ETF exchange traded funds that ALVO belongs to (by Net Assets): IBB, IDNA, EWX, PRFZ, IBBQ.
ALVO has underperformed the market in the last year with a price return of -40.3% while the SPY ETF gained +16.3%. However, in the short term, ALVO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +50.4% vs +4.4% return in SPY. But in the last 2 weeks, ALVO shares have been beat by the market, returning -16.4% compared to an SPY return of -0.8%.
ALVO support price is $4.90 and resistance is $5.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALVO shares will trade within this expected range on the day.